SCHEMBL17838995

SCHEMBL17838995

Fc1cc(Cl)cc2ncccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.62
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
L3MBTL1 Q9Y468 4/20 0.42
MPI P34949 1/20 0.42
SOS2 Q07890 1/20 0.42
ERN1 O75460 1/20 0.40
CCR1 P32246 2/20 0.40
CCR8 P51685 2/20 0.40
CCR5 P51681 1/20 0.40
ALDH1A1 P00352 1/20 0.39
SLC40A1 Q9NP59 1/20 0.38
SYK P43405 1/20 0.38
EGFR P00533 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PABPC1 P11940 1/20 0.38
EIF4H Q15056 1/20 0.38
GRM2 Q14416 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1160994 0.80 KDM4E (0.48) NR4A2KDM4EMAPTL3MBTL1MPI
SCHEMBL29870703 0.80 KDM4E (0.48) NR4A2KDM4EMAPTL3MBTL1MPI
SCHEMBL29702168 0.80 NR4A2 (0.67) NR4A2KDM4EMAPTL3MBTL1SOS2
SCHEMBL7712335 0.80 NR4A2 (0.67) NR4A2KDM4EMAPTL3MBTL1SOS2
SCHEMBL15765873 0.77 NR4A2 (0.62) NR4A2KDM4EMAPTL3MBTL1SOS2
SCHEMBL31606740 0.77 NR4A2 (0.62) NR4A2KDM4EMAPTL3MBTL1SOS2
SCHEMBL18572648 0.77 NR4A2 (0.62) NR4A2KDM4EMAPTL3MBTL1MPI
SCHEMBL2171872 0.77 NR4A2 (0.62) NR4A2KDM4EMAPTL3MBTL1SOS2
SCHEMBL29937108 0.77 ALDH1A1 (0.48) NR4A2KDM4EMAPTL3MBTL1MPI
SCHEMBL115816 0.77 NR4A2 (0.49) NR4A2KDM4EMAPTL3MBTL1MPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3237401-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR Pfizer Inc (US) 2017-11-01 EP disclosed
US-9738626-B2 Antagonists of prostaglandin EP3 receptor PFIZER INC. (US) 2017-08-22 US disclosed
WO-2016103097-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER INC. (US) 2016-06-30 WO disclosed
US-20160176851-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER INC. (US) 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176851-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PTGER3, PTGES3, PTGER2 NR4A2 560/4885KDM4E 3987/4885MAPT 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.